Abstract
The aim of this experiment was to study the effects of the antioxidant drug “U-74389G” on rat model, particularly in ischemia reperfusion protocol. The beneficial or other effects of that molecule were studied estimating the mean oophoritis (OI) lesions. Materials and methods: 40 rats were used of mean weight 231.875 g. OI was evaluated 60 min after reperfusion for groups A and C and 120 min after reperfusion for groups B and D. Groups A and B were without the drug but C and D with U-74389G administration. Results were that U-74389G administration kept non-significantly increased the OI scores by 0.05±0.051 without lesions (p=0.3204). Reperfusion time kept non-significantly increased the OI scores by 0.05±0.051 also without lesions (p=0.3204). Nevertheless, U-74389G administration and reperfusion time together kept non-significantly increased the OI scores by 0.045±0.030 (p=0.1334). Conclusions: Results of this study indicate that U-74389G administration, reperfusion time and their interaction declined the increased OI scores from significant to non-significant level.
Keywords: Oophoritis, reperfusion, U-74389G.
Graphical Abstract
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:The Effect of the Antioxidant Drug "U-74389G" on Oophoritis During Ischemia Reperfusion Injury in Rats
Volume: 13 Issue: 2
Author(s): Constantinos Τsompos, Constantinos Panoulis, Konstantinos Τοutouzas, George Ζografos and Apostolos Papalois
Affiliation:
Keywords: Oophoritis, reperfusion, U-74389G.
Abstract: The aim of this experiment was to study the effects of the antioxidant drug “U-74389G” on rat model, particularly in ischemia reperfusion protocol. The beneficial or other effects of that molecule were studied estimating the mean oophoritis (OI) lesions. Materials and methods: 40 rats were used of mean weight 231.875 g. OI was evaluated 60 min after reperfusion for groups A and C and 120 min after reperfusion for groups B and D. Groups A and B were without the drug but C and D with U-74389G administration. Results were that U-74389G administration kept non-significantly increased the OI scores by 0.05±0.051 without lesions (p=0.3204). Reperfusion time kept non-significantly increased the OI scores by 0.05±0.051 also without lesions (p=0.3204). Nevertheless, U-74389G administration and reperfusion time together kept non-significantly increased the OI scores by 0.045±0.030 (p=0.1334). Conclusions: Results of this study indicate that U-74389G administration, reperfusion time and their interaction declined the increased OI scores from significant to non-significant level.
Export Options
About this article
Cite this article as:
Τsompos Constantinos, Panoulis Constantinos, Τοutouzas Konstantinos, Ζografos George and Papalois Apostolos, The Effect of the Antioxidant Drug "U-74389G" on Oophoritis During Ischemia Reperfusion Injury in Rats, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2014; 13 (2) . https://dx.doi.org/10.2174/1871523013666140804230111
DOI https://dx.doi.org/10.2174/1871523013666140804230111 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Effects of Brain IKKβ Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model
CNS & Neurological Disorders - Drug Targets Curcumin Prevents Brain Damage and Cognitive Dysfunction During Ischemic-reperfusion Through the Regulation of miR-7-5p
Current Neurovascular Research Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cyclophilin D as a Drug Target
Current Medicinal Chemistry Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Synthesis, Antioxidant and Anti-inflammatoy Effects of Antioxidant Acid Amides with GABA and N-Acyl-pyrrolidin-2-ones
Current Chemical Biology Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Effect of Inhibitors of Nitric Oxide in Animal Models and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Neutrophil Gelatinase-associated Lipocalin as a Marker of Postoperative Acute Kidney Injury Following Cardiac Surgery in Patients with Preoperative Kidney Impairment
Cardiovascular & Hematological Disorders-Drug Targets Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews A Novel Assay Platform for the Detection of Translation Modulators of Spermidine/ Spermine Acetyltransferase
Current Pharmaceutical Design